There is currently no curative therapy for FRDA, however, recently omaveloxolone - a potent activator of nuclear factor erythroid 2-related factor 2 (NRF2) – has been shown to significantly improve neurological function [9] and thus has been approved as the first treatment for FRDA by the US Federal drug Administration (FDA) and the European Medicines Agency (EMA). Here, NFE2L2 is linked to Friedreich ataxia.